ARAY - Accuray Incorporated
| Previous close | 3.95 |
| Open | 3.95 |
| Bid | 3.85 x 500 |
| Ask | 4.10 x 3500 |
| Day's range | 3.90 - 4.00 |
| 52-week range | 3.60 - 6.15 |
| Volume | 315,214 |
| Avg. volume | 525,623 |
| Market cap | 342.552M |
| Beta | 2.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.34 |
| Earnings date | 16 Aug 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.20 |
- Zacks•29 days ago
Accuray's Radixact Gets AERB Nod in India, Prospects Solid
The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.
- Simply Wall St.•last month
At US$04.325, Is It Time To Buy Accuray Incorporated (NASDAQ:ARAY)?
Accuray Incorporated (NASDAQ:ARAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS over the last few months, increasingRead More...
- Zacks•last month
New Strong Sell Stocks for June 11th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•2 months ago
Here's Why You Should Sell Accuray (ARAY) Stock Right Now
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).
- Zacks•2 months ago
New Strong Sell Stocks for June 4th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•2 months ago
Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•2 months ago
Why Accuray, Cincinnati Bell, and Chesapeake Energy Slumped Today
Find out which company dealt with weak earnings.
- Zacks•2 months ago
New Strong Sell Stocks for May 23rd
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•2 months ago
New Strong Sell Stocks for May 17th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- PR Newswire•2 months ago
Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care
Accuray Incorporated (Nasdaq:ARAY) announced today the unveiling of a new corporate website that reflects the company's evolution and leadership in patient-first cancer treatment innovations. The fully redesigned, modern site puts critical disease and treatment information at the fingertips of website visitors, highlights the unique features and capabilities that set the company's radiotherapy tools-including the CyberKnife®, TomoTherapy® and Radixact® Systems-apart, and will serve as home base for details on future breakthroughs. As part of this, we continually introduce cancer treatment breakthroughs that help our customers improve clinical and economic outcomes.
- Zacks•3 months ago
Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top
Radixact System and major software overhaul drive Accuray (ARAY) in Q3.
- Associated Press•3 months ago
Accuray: Fiscal 3Q Earnings Snapshot
The Sunnyvale, California-based company said it had a loss of 10 cents per share. The radiation oncology company posted revenue of $99.8 million in the period. Accuray expects full-year revenue in the ...
- PR Newswire•3 months ago
Accuray to Bring Patient-First Cancer Treatment Innovations to ESTRO 37
Accuray Incorporated (Nasdaq:ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.
- Zacks•4 months ago
Accuray Radixact Picked by India's Apollo for Cancer Treatment
Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.
- Zacks•4 months ago
Accuray's CyberKnife Treats First Patient at Erasmus MC
Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.
- Zacks•4 months ago
Accuray Banks on Acquisition & Partnership Amid Competition
Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.
- PR Newswire•4 months ago
Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy With the CyberKnife® System
Accuray Incorporated (NASDAQ:ARAY) and Erasmus MC, the largest university medical center in the Netherlands, announced today that the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife® System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. "At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, MD, PhD, radiation oncologist, department of radiation oncology, Erasmus MC.
- Zacks•4 months ago
Accuray Gains on Radixact Unit, Solid Geographical Foothold
Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).
- Zacks•4 months ago
Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
- Market Realist•5 months ago
How Accuray Has Performed Financially
In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.
Market Realist•5 months agoHow Much Is Accuray’s Target Market Expected to Grow?
To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.
Market Realist•5 months agoWhat Analysts Recommend for Accuray in February 2018
Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.
- Market Realist•5 months ago
A Look at Accuray’s Therapy Systems
Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.
- Zacks•5 months ago
Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•5 months ago
Accuray's European AERO Academy Meeting: Innovation and Safety in the Field of Advanced Radiotherapy - Patients Come First
Accuray Incorporated (NASDAQ:ARAY) announced today highlights from its 2018 European AERO™ (Accuray Exchange in Radiation Oncology) Academy conference held in Lisbon, Portugal on January 26th and 27th. "Accuray is firmly committed to providing our customers with access to clinical thought leadership and forums that encourage treatment innovation. The AERO Academy events, both in the US and in Europe, are a driving force behind our patient-first philosophy," said Joshua H. Levine, President and Chief Executive Officer at Accuray.
